1 中华医学会结核病学分会.肺结核诊断和治疗指南[J].中华结核和呼吸杂志.2001,24(2) :70-74
2 Dy GK, AdjeiAA. Novel targets for lung cancer therapy [J]. J Clin Oncol, 2002,20:2881-2894
3 Fubuoka M, Yano S, Graccone G, et al. Multi-institutional ran dom ized phase II trial of Gefitinib for previously treated patients with advanced non-small cell lung cancer [J]. Clin Oncology,2003,21(12):2237-2246
4 LoRusso PM, Herbst RS, Rischin D,et al. Improvements in quali ty of life and disease-related symptoms in phase I trials of the se-lective oral epidermal growth factor receptor tyrosine kinase in hibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res, 2003,9:2040- 2048
5 Wu YL,Yang XN,Gu IJ. The characteristics of patients with non-small cell lung cancer with complete response treated with ZD1839[J]. Proc ASCO,2003,22:2770